Literature DB >> 12544829

Differences in dopaminergic neuroprotective effects of estrogen during estrous cycle.

Krishna P Datla1, Hilary E Murray, Arani V Pillai, Glenda E Gillies, David T Dexter.   

Abstract

Previous studies suggest that estrogen treatment protects nigrostriatal dopaminergic neurons, but have not examined whether the changes in estrogen levels during estrous cycle can influence the susceptibility of these neurons to neurotoxins. Here we show that the loss of dopaminergic neurons in the substantia nigra was greater in animals lesioned at diestrus (low estrogen) using 6-hydroxydopamine or buffered iron chloride, when compared with animals lesioned at proestrus (high estrogen). Lesioning at diestrus with 6-hydroxydopamine reduced the striatal dopamine content, whereas the dopamine content was preserved in animals lesioned at proestrus. The density of the dopamine transporter, upon which 6-hydroxydopamine toxicity is dependent, was lower when circulating estrogen was high. These results thus support a neuroprotectory role for estrogen. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12544829     DOI: 10.1097/00001756-200301200-00009

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  20 in total

1.  Risk factors for Parkinson's disease may differ in men and women: an exploratory study.

Authors:  Rodolfo Savica; Brandon R Grossardt; James H Bower; J Eric Ahlskog; Walter A Rocca
Journal:  Horm Behav       Date:  2012-06-08       Impact factor: 3.587

2.  Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease.

Authors:  Andrea Tamás; Andrea Lubics; István Lengvári; Dóra Reglodi
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

Review 3.  Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines.

Authors:  Glenda E Gillies; Simon McArthur
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

4.  Variants in estrogen-related genes and risk of Parkinson's disease.

Authors:  Sun Ju Chung; Sebastian M Armasu; Joanna M Biernacka; Timothy G Lesnick; David N Rider; Julie M Cunningham; Demetrius M Maraganore
Journal:  Mov Disord       Date:  2011-04-05       Impact factor: 10.338

5.  Gender differences in Parkinson's disease.

Authors:  Charlotte A Haaxma; Bastiaan R Bloem; George F Borm; Wim J G Oyen; Klaus L Leenders; Silvia Eshuis; Jan Booij; Dean E Dluzen; Martin W I M Horstink
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-11-10       Impact factor: 10.154

6.  PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease.

Authors:  Arnulfo Quesada; Becky Y Lee; Paul E Micevych
Journal:  Dev Neurobiol       Date:  2008-04       Impact factor: 3.964

7.  Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.

Authors:  Li Xu; Wen-Fang Chen; Man-Sau Wong
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

8.  The roles of membrane estrogen receptor subtypes in modulating dopamine transporters in PC-12 cells.

Authors:  Rebecca A Alyea; Stephanie E Laurence; Sung H Kim; Benita S Katzenellenbogen; John A Katzenellenbogen; Cheryl S Watson
Journal:  J Neurochem       Date:  2008-05-19       Impact factor: 5.372

9.  Effects of gender on nigral gene expression and parkinson disease.

Authors:  Ippolita Cantuti-Castelvetri; Christine Keller-McGandy; Bérengère Bouzou; Georgios Asteris; Timothy W Clark; Matthew P Frosch; David G Standaert
Journal:  Neurobiol Dis       Date:  2007-03-03       Impact factor: 5.996

10.  Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle.

Authors:  Anete Curte Ferraz; Francesca Matheussi; Raphael Escorsim Szawka; Vanessa Rizelio; Ana Márcia Delattre; Paula Rigon; Erica do Espírito Santo Hermel; Léder Leal Xavier; Matilde Achaval; Janete A Anselmo-Franci
Journal:  Neurochem Res       Date:  2008-02-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.